AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E40171-T1: [Translated] HAND OPERATED SECURITY CONTROL FOR ELECTRIC LOCKS, PARTICULARLY FOR MOTOR VEHICLES.

1. Claims for the contracting states : BE, CH, DE, GB, IT, LI, NL, SE Safety manual control for locks with an electric control or others, which includes, generally near the door of the driver, a box (1) fixed by convenient means onto the metal sheet (3) of the body of the vehicule in consideration, the box (1) insidely containing, in a recess (4), a microcontact (5) responsive to the electronic central unit controlling the locks of the vehicle and connected via a cable (6a) to a source of electric energy (16) for driving the motor (14) the shaft (13) of which carries a latch (12) normally held perpendicularly to an unblocking bar (8) by a spring, the motor and the battery being placed inside a recess (15a) of a second recessed bar (15) on which bears the unblocking bar (8) formed with a notch (11) provided for receiving the upper end (12a) of the latch (12), then the second bar (15) includes, in its portion situated opposite the motor (14), a cable clamp (17) providing for the junction of the cable (18) housed in a sleeve (19) and used for the manual unlatching control of the locks, the unblocking bar (8) and the recessed bar (15) which are surimposed and slide in the chamber (7) of the box (1) being held in position laterally by a plate (20) fixed onto the inner side of the box (1), then the outer end of the unblocking bar (8) presents a junction point (9) which can be actuated directly or indirectly by a key from the inside or the outside of the vehicle. 1. Claims for the contracting states : AT, LU Safety manual control for electrically controlled locks or others, which includes, generally near the door of the driver, a box (1) fixed by convenient means onto the metal sheet (3) of the body of the vehicule in consideration, a source of electric energy (16) for driving a motor (14), this control being characterized in that the box (1) insidely contains, in a cell (4), a microcontact (5) responsive to the central electronic unit for controlling the vehicle locks and connected via a cable (6a) to the source of electric energy (16) for driving the motor (14) the shaft (13) of which carries a latch (12) normally held perpendicularly to an unblocking bar (8) by a spring, the motor and the battery being placed inside a recess (15a) of a second recessed bar (15) on which bears the unblocking bar (8) formed with a notch (11) provided for receiving the upper end (12a) of the latch (12), then the second bar (15) includes, in its portion situated opposite the motor (14), a cable clamp (17) providing for the junction of the cable (18) housed in a sleeve (19) and used for the manual unlatching control of the locks, the unblocking bar (8) and the recessed bar (15) which are surimposed and slide inside the chamber (7) of the box (1) being held in position laterally by a plate (20) fixed on the inner side of the box (1), then the outer end of the unblocking bar (8) presents a junction point (9) which can be directly or indirectly actuated by a key from the inside or outside the vehicle.
NNDSS - TABLE 1JJ. Tuberculosis to Tularemia

NNDSS - TABLE 1JJ. Tuberculosis to Tularemia – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note:
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue

NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Compound 528595: Bis[tert-butyl(dimethyl)silyl] suberate

Chemical compound data from PubChem database. IUPAC Name: bis[tert-butyl(dimethyl)silyl] octanedioate. Molecular Formula: C20H42O4Si2. Molecular Weight: 402.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Stroke Mortality Data Among US Adults (35+) by State/Territory and County – 2015-2017

2015 to 2017, 3-year average. Rates are age-standardized. County rates are spatially smoothed. The data can be viewed by sex and race/ethnicity. Data source: National Vital Statistics System. Additional data, maps, and methodology can be viewed on the Interactive Atlas of Heart Disease and Stroke. 
http://www.cdc.gov/dhdsp/maps/atlas
Patent AT-E40133-T1: [Translated] ENANTIOMERICALLY PURE ACETALIC MONO-PROTECTED DIOLS, THEIR PREPARATION AND USE.

Enantiomerically pure mono acetal-protected diols of the formula <IMAGE>  I  wherein A, B, C and D are hydrogen or a methyl group in any combination, M and N are aliphatic or araliphatic hydrocarbons, m and n are the numbers 0, 1 or 2, whereby the total of m plus n must be the number 1 or 2, their preparation and use for the syntheses of the pheromones (1R-exo)-Brevicomin, (1S-exo)-Brevicomin, (1R-endo)-Brevicomin and (1S-endo)-Brevicomin.
Illicit Drug Use Tables (Prevalence Estimates) - 1.1 to 1.92

These detailed tables are population illicit drug use totals and prevalence estimates from the 2010 National Survey on Drug Use and Health (NSDUH). Illicit drugs include marijuana, cocaine, crack, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type psychotherapeutics, including pain relievers, tranquilizers, stimulants, and sedatives. Results are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area. Comparisons are made between 2010 and 2009.
The critically ill patient after hepatobiliary surgery

Background:
          We analyzed the causes and results of utilization of critical care
services in the special care unit in patients after surgical procedures
performed by the hepatobiliary surgical service during a 23-month period.
        
        
          Results:
          Thirty-two of 537 patients (6.0%) required postoperative admission
to the special care unit. Twenty-one patients were admitted directly from
operating room or from recovery room because of inability to wean from
ventilator (n = 10), hypovolemic shock (n = 4), myocardial
ischemia or infarction (n = 2), sepsis (n = 2), upper
gastrointestinal bleeding (n = 2), and acute renal failure (n
=1). Eleven postoperative patients were admitted from floor care for
respiratory failure (n = 4), cardiac dysrhythmia or infarction
(n = 4), sepsis (n = 2), and upper gastrointestinal bleeding
(n = 1). Thirty-eight per cent of patients (n = 12) admitted to
the special care unit after surgery died. By multivariate analysis, total
postoperative stay in the special care unit that was greater than median total
duration of stay of 4.5 days was the only independent predictor of mortality
(P = 0.041).
        
        
          Conclusions:
          Respiratory failure was the predominant component of all
complications after hepatobiliary surgery. No clinically useful predictors of
eventual outcome could be identified.
Minimizing charges associated with the determination of brain death

Background:
          The purpose of this study was to evaluate the effect of altering the use of the protocol for brain death determination in traumatically injured patients, on time to brain death determination, medical complication rates, organ procurement rates and charges for care rendered during brain death determination. A retrospective chart review of trauma patients with lethal brain injuries at an urban tertiary care trauma center was performed. Two groups of trauma patients with lethal head injuries were compared. Group I consisted of patients pronounced brain dead using a protocol requiring two brain examinations, and group II contained patients evaluated using a protocol requiring one brain examination in conjunction with a nuclear medicine brain flow scan.
        
        
          Results:
          Group II had a significantly (P < 0.01) shorter mean brain death stay (3.5 ± 1.8 h) than group I (12.0 ± 1.0 h). Patients in groups I and II developed a similar number of medical complications, 3.2 ± 0.2 and 4.0 ± 1.3, respectively. The number of organs procured per patient did not differ significantly (4.1 ± 0.2 for group I and 4.4 ± 1.4 for group II). There was a significant (P < 0.01) decrease in the brain death stay charges for group II ($6125 ± 1100) compared to group I ($16,645 ± 1223).
        
        
          Conclusions:
          Medical complications are universal in the traumatized patient awaiting the determination of brain death. These complications necessitate aggressive and costly care in the intensive care unit in order to optimize organ function in preparation for possible transplantation. In our institution, the determination of brain death using a single clinical examination and a nuclear medicine flow study significantly shortened the brain death stay and reduced associated charges accrued during this period. The complication and organ procurement rates were not affected in this small, preliminary report sample.
NCHS Research and Development Survey (RANDS) Round 4 Restricted File

The Research and Development Survey (RANDS) is a series of cross-sectional surveys using probability-sampled commercial survey panels. The fourth round of RANDS (RANDS 4) was administered by NORC at the University of Chicago using the AmeriSpeak Panel from July 17, 2020 to August 24, 2020. RANDS 4 contained the embedded probe questions and experiments as in previous rounds of RANDS, but had an emphasis on disability and the use of opioid pain relievers. RANDS 4 has a known survey sampling design and can be used to produce nationally and sub-nationally representative estimates.
Miscellaneous Tables (Prevalence Estimates) - 6.1 to 6.107

These detailed tables present totals and prevalence estimates of the number of days and types of substance use, poly-drug use, nicotine dependence, substance dependence by age of first use, source of substances, social context of substance use, and drunk/drugged driving from the 2012 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs, marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives, and alcohol. Results are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, geographic area, pregnancy status, college enrollment status, and probation/parole status. Comparisons are made between 2012 and 2011.
Compound 528294: 1,2,3,4,5-Pentamethylcyclohexane

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,4,5-pentamethylcyclohexane. Molecular Formula: C11H22. Molecular Weight: 154.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 1. Illicit Drug Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past month illicit drugs use by State and substate regions.
NSDUH 2019 Editing And Imputation Report

This report focuses on the editing and statistical imputation procedures that were applied to respondent data for the 2019 NSDUH. Logical editing uses data from elsewhere within the same respondent's record to reduce the occurrence of missing or ambiguous data or to resolve inconsistencies between related variables. Imputation is defined as the replacement of missing values with valid, nonmissing values. Statistical imputation usually involves some randomness to preserve the natural variability in the data.
CDC Best Practices for Comprehensive Tobacco Control Programs - 2007

2007. Centers for Disease Control and Prevention (CDC). Best Practices for Comprehensive Tobacco Control Programs. Funding. CDC's Best Practices for Comprehensive Tobacco Control Programs is an evidence-based guide to help states plan and establish effective tobacco control programs to prevent and reduce tobacco use.  Data are reported at total and per capita funding levels. Data include recommended, upper, and lower total funding levels for state programs, in addition to funding breakdowns by intervention areas such as: State and Community Interventions, Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Administration and Management.
COVID-19 State Profile Report - North Carolina

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Managed Care Individual Provider Network Data: March 31, 2012

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans.

This dataset reflects individual provider data.

Provider Network Data System information is self-reported.

For more information, check out: http://www.health.ny.gov/health_care/managed_care/.
Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports

Background
          This investigation was undertaken to describe patient perception and awareness of the polycystic ovary syndrome (PCOS), the most common cause of anovulation/oligoovulation among women of reproductive age.
        
        
          Methods
          Fifteen parameters were evaluated by a computer-based research instrument accessed by a large, unscreened population. Incomplete questionnaires were not entered, and responses were electronically tabulated to block duplicate submissions.
        
        
          Results
          From 657 participants, the majority (63%) were between 26–34 years old; mean BMI was 30.4 kg/m2. 343 of 657 had at least one pregnancy and 61% of the study group had taken fertility medicine (any type) at least once. Physicians were the most common provider of PCOS information for all study participants, irrespective of age. Patient emotions associated with the diagnosis of PCOS included "frustration" (67%), "anxiety" (16%), "sadness" (10%), and "indifference" (2%). Self-reported patient aptitude regarding PCOS was scored as high or "very aware" in >60% of women. Respondents were also asked: "If your PCOS could be safely and effectively helped by something else besides fertility drugs or birth control pills, would that interest you?" Interest in alternative PCOS treatments was expressed by 99% of the sample (n = 648).
        
        
          Conclusions
          In our study population, most women associated negative emotions with PCOS although the self-reported knowledge level for the disorder was high. While these women regarded their obstetrician-gynecologist as integral to their PCOS education, traditional PCOS therapies based on oral contraceptives or ovulation induction agents were regarded as unsatisfactory by most women.